Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Cornelissen Bart JanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:190,194Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Cornelissen Bart JanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:42,265Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Kuch John JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-849Price:$23.50
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Eckert CeliaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-850Price:$23.50
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Desjarlais John ROwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,280Price:$23.50
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Dahiyat Bassil IOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,741Price:$23.50
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Gustafson Kurt AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Gustafson Kurt AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,000Price:$23.18
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Gustafson Kurt AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,000Price:$10.73
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Valente NancyOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:117,801Price:--
Filings by filing date
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Cornelissen Bart JanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:190,194Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Cornelissen Bart JanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:42,265Price:--
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Kuch John JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-849Price:$23.50
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Eckert CeliaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-850Price:$23.50
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Desjarlais John ROwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,280Price:$23.50
-
Mar 11, 2024 (filed on Mar 12, 2024)Insider Name:Dahiyat Bassil IOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,741Price:$23.50
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Gustafson Kurt AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Gustafson Kurt AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,000Price:$23.18
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Gustafson Kurt AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:15,000Price:$10.73
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Valente NancyOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:117,801Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 465 N. HALSTEAD ST., SUITE 200 PASADENA CA 91107 |
Tel: | N/A |
Website: | https://xencor.com |
IR: | See website |
Key People | ||
Bassil I. Dahiyat President, Chief Executive Officer, Founder and Director | Bart Cornelissen Chief Financial Officer, Senior Vice President | John R. Desjarlais Executive Vice President - Research, Chief Scientific Officer |
Nancy Valente Executive Vice President, Chief Development Officer | Celia E. Eckert Senior Vice President, General Counsel, Company Secretary | Dane Leone Senior Vice President, Corporate Strategy |
Business Overview |
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4. |
Financial Overview |
For the fiscal year ended 31 December 2023, Xencor Inc revenues increased 2% to $168.3M. Net loss increased from $55.2M to $126.1M. Revenues reflect Milestone segment increase from $5.5M to $88.5M, Research collaboration segment increase from $7M to $30.3M. Higher net loss reflects Research and Development - Balancing increase of 30% to $219.1M (expense), Stock-based Compensation in R&D increase of 9% to $34.5M (expense). |
Employees: | 280 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $602.59M as of Dec 31, 2023 |
Annual revenue (TTM): | $168.34M as of Dec 31, 2023 |
EBITDA (TTM): | -$126.64M as of Dec 31, 2023 |
Net annual income (TTM): | -$126.09M as of Dec 31, 2023 |
Free cash flow (TTM): | $63.86M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 61,647,493 as of Apr 15, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |